In conclusion, treating iron deficiency by targeting hepcidin or IL-6 signaling or rebalancing the BMP-/TGF-β-dependent pathways represents innovative strategies that need to be addressed as complements to conventional therapies in robust clinical trials. The gene discussed is TGFB1; the disease is nutritional disorder.